Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-212082 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study. |
| Name | Type | Description |
|---|---|---|
| JNJ-212082 | DRUG | 250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study. |
Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate, but not with neuroendocrine differentiation or of small cell histology * No Prior cytotoxic chemotherapy (including estramustine) for the treatment of prostate cancer * Surgically or medically castrated,...
JNJ-212082 is an investigational small molecule being developed for the treatment of prostatic neoplasms, which are tumors of the prostate. It is currently in Phase 1 clinical development. The drug is being studied in patients with castration-resistant prostate cancer, a form of the disease that progresses despite hormone therapy.
JNJ-212082 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for the treatment of prostate cancer.
JNJ-212082 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The Phase 1 trial for JNJ-212082 has been completed, and the drug remains in early-stage clinical development.
JNJ-212082 has been studied in one completed Phase 1 clinical trial, identified as NCT01186484. This trial was titled 'Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer' and enrolled 27 male patients in Japan. The study was uncontrolled, meaning there was no comparator group, and it was not randomized or double-blinded.
JNJ-212082 is associated with abiraterone acetate, as the completed Phase 1 clinical trial NCT01186484 was titled 'Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer.' The trial enrolled 27 patients with prostatic neoplasms in Japan. JNJ-212082 is the investigational drug being studied in this trial.